| scholarly article | Q13442814 |
| P50 | author | Daniel J. Sargent | Q43055483 |
| P2093 | author name string | Sumithra J Mandrekar | |
| Ming-Wen An | |||
| P2860 | cites work | Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. | Q51911724 |
| Designs for group sequential phase II clinical trials. | Q52583941 | ||
| Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset | Q56528613 | ||
| An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies | Q80107489 | ||
| Evaluating the efficiency of targeted designs for randomized clinical trials | Q80901366 | ||
| Adaptive clinical trials: the promise and the caution | Q82966805 | ||
| Limitations of adaptive clinical trials | Q87145039 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| Interim analyses for randomized clinical trials: the group sequential approach | Q28278223 | ||
| Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine | Q33827699 | ||
| Effective incorporation of biomarkers into phase II trials | Q33870594 | ||
| The BATTLE trial: personalizing therapy for lung cancer | Q34275011 | ||
| Outcome--adaptive randomization: is it useful? | Q34667846 | ||
| All-comers versus enrichment design strategy in phase II trials | Q34857268 | ||
| Design of clinical trials for biomarker research in oncology | Q35789708 | ||
| A 2-stage phase II design with direct assignment option in stage II for initial marker validation | Q36170160 | ||
| Randomized phase II trial designs with biomarkers | Q36212448 | ||
| Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. | Q37325013 | ||
| Biomarkers and surrogate end points--the challenge of statistical validation | Q37724573 | ||
| Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. | Q37969774 | ||
| Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer | Q42634968 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phase II clinical trial | Q42824440 |
| P304 | page(s) | 597-604 | |
| P577 | publication date | 2013-05-08 | |
| P1433 | published in | Contemporary Clinical Trials | Q5164971 |
| P1476 | title | A review of phase II trial designs for initial marker validation | |
| P478 | volume | 36 |
| Q35206844 | Adaptive clinical trial designs in oncology |
| Q55052878 | Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines. |
| Q26766584 | Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q37731264 | Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review |
| Q90452339 | Discussion of Trial Designs for Biomarker Identification and Validation Through the Use of Case Studies |
| Q34535243 | Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine |
| Q64965659 | Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating? |
| Q38639549 | Is the NCI MATCH trial a match for gynecologic oncology? |
| Q64063419 | Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape |
| Q28086970 | Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review |
| Q26786724 | Molecular and clinical implementations of ovarian cancer mouse avatar models |
| Q95282127 | Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference |
Search more.